ArticleMicrobial biotechnology2025

Baseline Fusobacterium Abundance Predicts Ustekinumab Response in Crohn's Disease: A Prospective Microbiome Cohort Study.

Chengran Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.